Clinical Trial

Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will assess the safety and efficacy of topical ruxolitinib for treating the refractory cutaneous manifestations in patients with dermatomyositis. The investigators' hypothesis is that topical ruxolitinib will be both safe and effective for such patients.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-03; most recent amendment 2025-10-03.
Status change: Not Yet Recruiting → Recruiting 2025-07-17
Trial Details
NCT Number NCT06857240
Lead Sponsor The Cleveland Clinic
Conditions Dermatomyositis
Enrollment 15 participants
Start Date 2025-06-01
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-08